Almirall, S.A. (0O9B.IL)
| Previous close | 9.61 |
| Open | 9.57 |
| Bid | 9.45 x 0 |
| Ask | 9.90 x 0 |
| Day's range | 9.57 - 9.68 |
| 52-week range | 7.20 - 10.33 |
| Volume | |
| Avg. volume | 96,487 |
| Market cap | 2.024B |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.06 |
| Earnings date | N/A |
| Forward dividend & yield | 0.18 (1.94%) |
| Ex-dividend date | 12 May 2023 |
| 1y target est | N/A |
- Investing.com
Almirall's Ebglyss poised for EU approval, challenging Sanofi and Regeneron’s Dupixent
Almirall, the Spanish pharmaceutical company, is on the brink of securing European Union (EU) approval for its IL-13 inhibitor lebrikizumab, marketed as Ebglyss, for atopic dermatitis treatment. The European Medicines Agency's (EMA) human medicines committee has recommended the drug's approval, setting up a challenge to the market-leading Dupixent, produced by Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN).
Business WireEBGLYSS® (lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis
BARCELONA, Spain, September 15, 2023--Almirall S.A. (BME: ALM) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the marketing authorization of EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate-to-severe atopic dermatitis, who are candidates for systemic therapy.
Business WireAlmirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business
BARCELONA, Spain, July 24, 2023--Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its H1 2023 financial results.
